Danielle Ternyila

Articles

Secord Shares Data to Digest With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Three pivotal clinical trials evaluating PARP inhibitors have significantly impacted the treatment of patients with newly diagnosed ovarian cancer.

Novel PARP Combinations Boost Responses in Ovarian Cancer

February 9th 2020

Floor J. Backes, MD, discusses the latest advancements made in the treatment of patients with ovarian cancer and the ongoing research efforts that are being made with novel combinations.

Rule Reflects on Continued Benefit With Ibrutinib in Relapsed/Refractory MCL

February 7th 2020

Simon Rule, MD, PhD, discusses pooled findings examining ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Mesa Shares Insight on Fedratinib Benefit in Myelofibrosis Subgroup

January 30th 2020

Ruben Mesa, MD, discusses findings from a pooled analysis of fedratinib at full dose in patients with myelofibrosis who had low platelet counts.

FDA Grants ADP-A2M4 RMAT Designation for Synovial Sarcoma

December 23rd 2019

The FDA has granted a Regenerative Medicine Advanced Therapy designation to ADP-A2M4 (MAGE-A4) as a treatment for patients with synovial sarcoma.

FDA Grants SP-2577 Fast Track Status for Ewing Sarcoma

December 23rd 2019

The FDA has granted fast track designation to the potent reversible LSD1 inhibitor SP-2577 (seclidemstat) for the treatment of relapsed/refractory patients with Ewing sarcoma.

Maintenance Rituximab After R-CHOP Shows Continued Benefit in Older Patients With MCL

December 23rd 2019

Induction therapy with R-CHOP followed by maintenance rituximab continued to show improvements in survival and responses compared with R-CHOP and interferon-alpha maintenance in older patients with mantle cell lymphoma.

PARP Inhibitors Gain a Foothold in Prostate Cancer

December 12th 2019

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.

Targeted Therapies Continue to Evolve in Metastatic NSCLC

December 2nd 2019

The proliferation of targeted therapies in non–small cell lung cancer has helped improve overall survival for patients with metastatic disease and illustrates the importance of molecular testing,

Expert Weighs in on Targeted and Immunotherapy Combinations in Melanoma

November 26th 2019

Ryan J. Sullivan, MD, discusses the rationale for BRAF/MEK combinations and immunotherapeutic combinations in melanoma and ongoing research examining triplet regimens.

Expert Highlights Potential Markers of Nivolumab/Ipilimumab Response in Melanoma

November 26th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the findings from a subgroup analyses of the CheckMate-067 trial.

Targeted Combos Improve OS in Melanoma, But Mitigating Toxicities Essential

November 23rd 2019

Adil Daud, MD, discusses the role of dabrafenib plus trametinib in patients with advanced melanoma and highlighted other combinations under investigation.

Rising Incidence of Fatty Liver Disease Holds Implications for Trends in HCC

November 13th 2019

Nonalcoholic fatty liver disease, a risk factor linked to the development of hepatocellular carcinoma and increased mortality, is growing in clinical significance.

Can Combo of Vemurafenib and Obinutuzumab Shake Up Hairy Cell Leukemia Paradigm?

October 26th 2019

The standard of care for the frontline treatment of patients with hairy cell leukemia has been purine nucleoside analogs, including pentostatin and cladribine; however, investigators are challenging this treatment in a phase II clinical trial with a targeted therapy that may provide similar benefit with fewer toxicities.

Ongoing Trial Demonstrates Promising PFS With Ibrutinib in Hairy Cell Leukemia

October 25th 2019

Kerry Rogers, MD, discusses the potential of ibrutinib (Imbruvica) in hairy cell leukemia, emerging treatment options such as moxetumomab pasudotox (Lumoxiti), and next steps and challenges in the field.

Long-Term Data Highlight Poor Prognosis With TP53-Mutant MCL

October 11th 2019

Ezzat Elhassadi, MD, discusses the results from a 10-year institutional analysis and how the presence of a TP53 mutation can correlate with survival outcomes in patients with mantle cell lymphoma.

Rugo Highlights Latest Advances in TNBC Treatment

October 6th 2019

Hope S. Rugo, MD, discusses the latest advancements in the treatment landscape for patients with TNBC and highlights some data from clinical trials presented at the 2019 ESMO Congress.

Inflammatory Breast Cancer Has Diagnostic Challenges, Requires More Awareness

October 5th 2019

Naoto Tada Ueno, MD, PhD, FACP, discusses the diagnosis and treatment of patients with inflammatory breast cancer and highlights the biggest challenges in both diagnosing and treating this patient population.

Patient Selection Key When De-Escalating Radiation in Breast Cancer

October 5th 2019

Jonathan B. Strauss, MD, MBA, discussed the role of hypofractionated radiotherapy in patients with breast cancer and offered advice on treatment selection.

PARP Inhibition Arrives in Pancreatic Cancer

August 9th 2019

Michael J. Hall, MD, Fox Chase Cancer Center, discusses the emergence of PARP inhibition in the armamentarium for patients with pancreatic cancer.